最近获得 FDA 批准的抗癌药物的临床疗效和作用机制:最新综述

Shikha Sharma, Anurag Agrawal, Anuj Kumar Singh, B. Banik
{"title":"最近获得 FDA 批准的抗癌药物的临床疗效和作用机制:最新综述","authors":"Shikha Sharma, Anurag Agrawal, Anuj Kumar Singh, B. Banik","doi":"10.2174/0115733947301362240330090709","DOIUrl":null,"url":null,"abstract":"\n\nSince the beginning of the 21st century, there have been significant advancements in the\nfield of cancer treatment, resulting in markedly improved outcomes for patients. This review provides\nan updated view of some recently developed and FDA-approved small molecules that have been used\nto treat various types of cancer on different indications and targets. Some popular search engines,\nsuch as Pubmed, Google Scholar, etc., were considered for the literature review, and drugs approved\nby the FDA from 2019 to 2023 were considered for study in this review. This review focuses on the\nmechanism of actions and targets via which these FDA-approved small molecules could demonstrate\ntheir clinical efficacy. Moreover, this review would pave the way for the scientific community to look\ninto the chemical structures of these small molecules to discover more small synthetic compounds\nafter modification based on structural activity that might be useful in treating various types of cancer.\nHowever, much attention is being paid to how new therapies and tools will change how cancer is\ntreated in the coming years. This review indicated the increased rate of approvals by the FDA for oncology\ntreatment during 2019-2023. This surge is primarily driven by the approval of targeted therapies\nand the introduction of novel therapeutic approaches.\n","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"58 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Efficacy and Mechanism of Action of Recently FDA Approved\\nAnticancer Drugs: An Updated Review\",\"authors\":\"Shikha Sharma, Anurag Agrawal, Anuj Kumar Singh, B. Banik\",\"doi\":\"10.2174/0115733947301362240330090709\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nSince the beginning of the 21st century, there have been significant advancements in the\\nfield of cancer treatment, resulting in markedly improved outcomes for patients. This review provides\\nan updated view of some recently developed and FDA-approved small molecules that have been used\\nto treat various types of cancer on different indications and targets. Some popular search engines,\\nsuch as Pubmed, Google Scholar, etc., were considered for the literature review, and drugs approved\\nby the FDA from 2019 to 2023 were considered for study in this review. This review focuses on the\\nmechanism of actions and targets via which these FDA-approved small molecules could demonstrate\\ntheir clinical efficacy. Moreover, this review would pave the way for the scientific community to look\\ninto the chemical structures of these small molecules to discover more small synthetic compounds\\nafter modification based on structural activity that might be useful in treating various types of cancer.\\nHowever, much attention is being paid to how new therapies and tools will change how cancer is\\ntreated in the coming years. This review indicated the increased rate of approvals by the FDA for oncology\\ntreatment during 2019-2023. This surge is primarily driven by the approval of targeted therapies\\nand the introduction of novel therapeutic approaches.\\n\",\"PeriodicalId\":503819,\"journal\":{\"name\":\"Current Cancer Therapy Reviews\",\"volume\":\"58 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Cancer Therapy Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115733947301362240330090709\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cancer Therapy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733947301362240330090709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

进入 21 世纪以来,癌症治疗领域取得了重大进展,患者的治疗效果明显改善。本综述介绍了最近开发并获得 FDA 批准的一些小分子药物,这些药物已被用于治疗不同类型癌症的不同适应症和靶点。文献综述考虑了一些流行的搜索引擎,如Pubmed、Google Scholar等,并将FDA在2019年至2023年批准的药物作为本综述的研究对象。本综述的重点是这些经 FDA 批准的小分子药物的作用机制和靶点,通过这些作用机制和靶点,这些药物可以展示其临床疗效。此外,本综述还将为科学界研究这些小分子化合物的化学结构铺平道路,以便根据结构活性进行修饰后发现更多可能有助于治疗各类癌症的小合成化合物。本综述指出,2019-2023 年期间,美国食品及药物管理局批准的肿瘤治疗药物数量将有所增加。这种激增主要是由靶向疗法的批准和新型治疗方法的引入所推动的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical Efficacy and Mechanism of Action of Recently FDA Approved Anticancer Drugs: An Updated Review
Since the beginning of the 21st century, there have been significant advancements in the field of cancer treatment, resulting in markedly improved outcomes for patients. This review provides an updated view of some recently developed and FDA-approved small molecules that have been used to treat various types of cancer on different indications and targets. Some popular search engines, such as Pubmed, Google Scholar, etc., were considered for the literature review, and drugs approved by the FDA from 2019 to 2023 were considered for study in this review. This review focuses on the mechanism of actions and targets via which these FDA-approved small molecules could demonstrate their clinical efficacy. Moreover, this review would pave the way for the scientific community to look into the chemical structures of these small molecules to discover more small synthetic compounds after modification based on structural activity that might be useful in treating various types of cancer. However, much attention is being paid to how new therapies and tools will change how cancer is treated in the coming years. This review indicated the increased rate of approvals by the FDA for oncology treatment during 2019-2023. This surge is primarily driven by the approval of targeted therapies and the introduction of novel therapeutic approaches.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Revolutionizing Oral Cancer Treatment: Immunotherapeutic Approaches Breast Cancer Diagnosis Using Computational Model: Recent Advancement Clinical Efficacy and Mechanism of Action of Recently FDA Approved Anticancer Drugs: An Updated Review Prevalence of Cervical Cancer and Premalignant Cases Based on Pap Smear Screening in Iran in 2022 Precision Genome Editing: The Synergy of CRISPR and Nanotechnology in Cancer Treatment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1